Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GSPWR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Alpha-CD30-Val-Cit-MMAE
|
|||||
| Synonyms |
AlphaCD30 vcMMAE
Click to Show/Hide
|
|||||
| Organization |
Oxford BioTherapeutics Ltd.; Seagen Inc.
|
|||||
| Drug Status |
Terminated
|
|||||
| Indication |
In total 1 Indication(s)
Hodgkin lymphoma [ICD11:2B30]
Terminated
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CD30 alphaCD30-vcMMAE mAb
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.